Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tracy L Diamond

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Journal of the International AIDS Society|June 19, 2025
Effectiveness of islatravir post-exposure prophylaxis after intravenous challenge with simian immunodeficiency virus in rhesus macaquesMartin Markowitz, Agegnehu Gettie, Leslie St Bernard, et al.
The Journal of Biological Chemistry|September 29, 2004
Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptaseTracy L Diamond, Mikhail Roshal, Varuni K Jamburuthugoda, et al.
Protein Expression and Purification|January 12, 2010
Purification of untagged HIV-1 reverse transcriptase by affinity chromatographyMeiqing Lu, Winnie Ngo, Ye Mei, et al.
Bioorganic & Medicinal Chemistry Letters|March 17, 2020
Discovery of 4-arylquinoline-2-carboxamides, highly potent and selective class of mGluR2 negative allosteric modulators: From HTS to activity in animal modelsYouheng Shu, Tracy L Diamond, James C Hershey, et al.
The Journal of Infectious Diseases|May 29, 2026
Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations or M184I/V in Proviral DNATracy L Diamond, Anjana Grandhi, Monica Fuszard, et al.
International Journal of Molecular Sciences|January 25, 2025
An Immunocytochemistry Method to Investigate the Translationally Active HIV ReservoirGuoxin Wu, Samuel H Keller, Ryan T Walters, et al.
The Journal of Infectious Diseases|December 16, 2025
Weekly Oral Prophylaxis With MK-8527 Protects Rhesus Macaques From Intrarectal Challenge With Simian-Human Immunodeficiency VirusTracy L Diamond, Yash Kapoor, Fangbiao Li, et al.
The Lancet. HIV|February 28, 2026
Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trialJürgen K Rockstroh, Sheetal Kassim, Roger Paredes, et al.
Plos Pathogens|May 30, 2009
Host cell factors in HIV replication: meta-analysis of genome-wide studiesFrederic D Bushman, Nirav Malani, Jason Fernandes, et al.
ACS Chemical Biology|October 13, 2017
Discovery of a Distinct Chemical and Mechanistic Class of Allosteric HIV-1 Integrase Inhibitors with Antiretroviral ActivityChristine Burlein, Cheng Wang, Min Xu, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Journal of the International AIDS Society|June 19, 2025
Effectiveness of islatravir post-exposure prophylaxis after intravenous challenge with simian immunodeficiency virus in rhesus macaquesMartin Markowitz, Agegnehu Gettie, Leslie St Bernard, et al.
The Journal of Biological Chemistry|September 29, 2004
Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptaseTracy L Diamond, Mikhail Roshal, Varuni K Jamburuthugoda, et al.
Protein Expression and Purification|January 12, 2010
Purification of untagged HIV-1 reverse transcriptase by affinity chromatographyMeiqing Lu, Winnie Ngo, Ye Mei, et al.
Bioorganic & Medicinal Chemistry Letters|March 17, 2020
Discovery of 4-arylquinoline-2-carboxamides, highly potent and selective class of mGluR2 negative allosteric modulators: From HTS to activity in animal modelsYouheng Shu, Tracy L Diamond, James C Hershey, et al.
The Journal of Infectious Diseases|May 29, 2026
Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations or M184I/V in Proviral DNATracy L Diamond, Anjana Grandhi, Monica Fuszard, et al.
International Journal of Molecular Sciences|January 25, 2025
An Immunocytochemistry Method to Investigate the Translationally Active HIV ReservoirGuoxin Wu, Samuel H Keller, Ryan T Walters, et al.
The Journal of Infectious Diseases|December 16, 2025
Weekly Oral Prophylaxis With MK-8527 Protects Rhesus Macaques From Intrarectal Challenge With Simian-Human Immunodeficiency VirusTracy L Diamond, Yash Kapoor, Fangbiao Li, et al.
The Lancet. HIV|February 28, 2026
Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trialJürgen K Rockstroh, Sheetal Kassim, Roger Paredes, et al.
Plos Pathogens|May 30, 2009
Host cell factors in HIV replication: meta-analysis of genome-wide studiesFrederic D Bushman, Nirav Malani, Jason Fernandes, et al.
ACS Chemical Biology|October 13, 2017
Discovery of a Distinct Chemical and Mechanistic Class of Allosteric HIV-1 Integrase Inhibitors with Antiretroviral ActivityChristine Burlein, Cheng Wang, Min Xu, et al.
Pageof 3